Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

References

• Konno T , MaedaH, IwaiKet al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur. J. Cancer Clin. Oncol.19(8), 1053–1065 (1983).
   PubMedGoogle Scholar
• Pelletier G , RocheA, LinkO, EtColl. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J. Hepatol.11, 181–184 (1990).
   PubMed Web of Science ®Google Scholar
• Hepatocellulaire GDEEDTDC . A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. N. Engl. J. Med.332(19), 1256–1261 (1995).
   PubMed Web of Science ®Google Scholar
• Lo CM , NganH, TsoWKet al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology35(5), 1164–1171 (2002).
   PubMed Web of Science ®Google Scholar
• Llovet JM , RealMI, MontanaXet al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet359(9319), 1734–1739 (2002).
   PubMed Web of Science ®Google Scholar
• Llovet J , DucreuxM, LencioniRet al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur. J. Cancer48(5), 599–641 (2012).
   PubMed Web of Science ®Google Scholar
• Ernst O , SergentG, MizrahiD, DelemazureO, ParisJC, L’hermineC. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJR Am. J. Roentgenol.172(1), 59–64 (1999).
   PubMed Web of Science ®Google Scholar
• Pelletier G , DucreuxM, GayFet al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J. Hepatol.29, 129–134 (1998).
   PubMed Web of Science ®Google Scholar
• De Baere T , AraiY, LencioniRet al. Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc. Intervent. Radiol. doi:10.1007/s00270-015-1208-y(pii) (2015) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Ikeda M , AraiY, ParkSJet al. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J. Vasc. Interv. Radiol.24(4), 490–500 (2013).
   PubMed Web of Science ®Google Scholar
• Golfieri R , GiampalmaE, RenzulliMet al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br. J. Cancer111(2), 255–264 (2014).
   PubMed Web of Science ®Google Scholar
• Kudo M , HanG, FinnRSet al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized Phase III trial. Hepatology60(5), 1697–1707 (2014).
   PubMed Web of Science ®Google Scholar
• Iwazawa J , OhueS, MitaniTet al. Identifying feeding arteries during TACE of hepatic tumors: comparison of C-arm CT and digital subtraction angiography. AJR Am. J. Roentgenol.192(4), 1057–1063 (2009).
   PubMed Web of Science ®Google Scholar
• Kakeda S , KorogiY, OhnariNet al. Usefulness of cone-beam volume CT with flat panel detectors in conjunction with catheter angiography for transcatheter arterial embolization. J. Vasc. Interv. Radiol.18(12), 1508–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Wallace MJ , MurthyR, KamatPPet al. Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J. Vasc. Interv. Radiol.18(12), 1500–1507 (2007).
   PubMed Web of Science ®Google Scholar
• Virmani S , RyuRK, SatoKTet al. Effect of C-arm angiographic CT on transcatheter arterial chemoembolization of liver tumors. J. Vasc. Interv. Radiol.18(10), 1305–1309 (2007).
   PubMed Web of Science ®Google Scholar
• Miyayama S , YamashiroM, HashimotoMet al. Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma </= 6 cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography. Cardiovasc. Intervent. Radiol.37(2), 388–395 (2014).
   PubMed Web of Science ®Google Scholar
• Deschamps F , SolomonSB, ThorntonRHet al. Computed analysis of three-dimensional cone-beam computed tomography angiography for determination of tumor-feeding vessels during chemoembolization of liver tumor: a pilot study. Cardiovasc. Intervent. Radiol.33(6), 1235–1242 (2010).
   PubMed Web of Science ®Google Scholar
• Iwazawa J , OhueS, HashimotoN, MitaniT. Comparison of the number of image acquisitions and procedural time required for transarterial chemoembolization of hepatocellular carcinoma with and without tumor-feeder detection software. Radiol. Res. Pract.2013, 580839 (2013).
   PubMedGoogle Scholar
• Lencioni R , De BaereT, BurrelMet al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc. Intervent. Radiol.35(5), 980–985 (2012).
   PubMed Web of Science ®Google Scholar
• Marelli L , StiglianoR, TriantosCet al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol.30(1), 6–25 (2007).
   PubMed Web of Science ®Google Scholar
• Bouvier A , OzenneV, AubeCet al. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur. Radiol.21(8), 1719–1726 (2011).
   PubMed Web of Science ®Google Scholar
• Golfieri R , CappelliA, CucchettiAet al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology53(5), 1580–1589 (2011).
   PubMed Web of Science ®Google Scholar
• Irie T , KuramochiM, TakahashiN. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovasc. Intervent. Radiol.36(3), 706–713 (2013).
   PubMed Web of Science ®Google Scholar
• Arai H , AbeT, TakayamaHet al. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol. Res.45(6), 663–666 (2015).
   PubMed Web of Science ®Google Scholar
• Jordan O , DenysA, De BaereT, BoulensN, DoelkerE. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J. Vasc. Interv. Radiol.21(7), 1084–1090 (2010).
   PubMed Web of Science ®Google Scholar
• Namur J , WassefM, MillotJM, LewisAL, ManfaitM, LaurentA. Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. J. Vasc. Interv. Radiol.21(2), 259–267 (2010).
   PubMed Web of Science ®Google Scholar
• Namur J , CitronSJ, SellersMTet al. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J. Hepatol.55(6), 1332–1338 (2011).
   PubMed Web of Science ®Google Scholar
• Hong K , KhwajaA, LiapiE, TorbensonMS, GeorgiadesCS, GeschwindJF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin. Cancer Res.12(8), 2563–2567 (2006).
   PubMed Web of Science ®Google Scholar
• Malagari K , PomoniM, KelekisAet al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc. Intervent. Radiol.33(3), 541–551 (2010).
   PubMed Web of Science ®Google Scholar
• Nicolini A , MartinettiL, CrespiS, MaggioniM, SangiovanniA. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J. Vasc. Interv. Radiol.21(3), 327–332 (2010).
   PubMed Web of Science ®Google Scholar
• Malagari K , PomoniM, MoschourisHet al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30–60 mum. Safety and efficacy study. Cardiovasc. Intervent. Radiol.37(1), 165–175 (2014).
   PubMed Web of Science ®Google Scholar
• Varela M , RealMI, BurrelMet al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol.46(3), 474–481 (2007).
   PubMed Web of Science ®Google Scholar
• Frenette CT , OsorioRC, StarkJet al. Conventional TACE and drug-eluting bead TACE as locoregional therapy before orthotopic liver transplantation: comparison of explant pathologic response. Transplantation98(7), 781–787 (2014).
   PubMed Web of Science ®Google Scholar
• Nicolini D , Svegliati-BaroniG, CandelariRet al. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J. Gastroenterol.19(34), 5622–5632 (2013).
   PubMed Web of Science ®Google Scholar
• Sacco R , BargelliniI, BertiniMet al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol.22(11), 1545–1552 (2011).
   PubMed Web of Science ®Google Scholar
• Van Malenstein H , MaleuxG, VandecaveyeVet al. A randomized Phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie34(7), 368–376 (2011).
   PubMedGoogle Scholar
• Lammer J , MalagariK, VoglTet al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol.33(1), 41–52 (2010).
   PubMed Web of Science ®Google Scholar
• Vogl TJ , LammerJ, LencioniRet al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am. J. Roentgenol.197(4), W562–W570 (2011).
   PubMed Web of Science ®Google Scholar
• Han S , ZhangX, ZouLet al. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PLoS ONE9(8), e102686 (2014).
   PubMed Web of Science ®Google Scholar
• Gao S , YangZ, ZhengZet al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology60(124), 813–820 (2013).
   PubMedGoogle Scholar
• Huang K , ZhouQ, WangR, ChengD, MaY. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J. Gastroenterol. Hepatol.29(5), 920–925 (2014).
   PubMed Web of Science ®Google Scholar
• Lee KH , LiapiE, VossenJAet al. Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J. Vasc. Interv. Radiol.19(10), 1490–1496 (2008).
   PubMed Web of Science ®Google Scholar
• Laurent A , WassefM, ChapotRet al. Partition of calibrated tris-acryl gelatin microspheres in the arterial vasculature of embolized nasopharyngeal angiofibromas and paragangliomas. J. Vasc. Interv. Radiol.16(4), 507–513 (2005).
   PubMed Web of Science ®Google Scholar
• Malagari K , PomoniM, MoschourisHet al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc. Intervent. Radiol.35(5), 1119–1128 (2012).
   PubMed Web of Science ®Google Scholar
• Padia SA , ShivaramG, BastawrousSet al. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. J. Vasc. Interv. Radiol.24(3), 301–306 (2013).
   PubMed Web of Science ®Google Scholar
• Malagari K , PomoniM, SpyridopoulosTNet al. Safety profile of sequential transcatheter chemoembolization with DC Bead: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc. Intervent. Radiol.34(4), 774–785 (2011).
   PubMed Web of Science ®Google Scholar
• Deipolyi AR , OkluR, Al-AnsariS, ZhuAX, GoyalL, GanguliS. Safety and efficacy of 70–150 mum and 100–300 mum drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol.26(4), 516–522 (2015).
   PubMed Web of Science ®Google Scholar
• Guiu B , DeschampsF, AhoSet al. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J. Hepatol.56(3), 609–617 (2012).
   PubMed Web of Science ®Google Scholar
• Bonomo G , PediciniV, MonfardiniLet al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc. Intervent. Radiol.33(3), 552–559 (2010).
   PubMed Web of Science ®Google Scholar
• Scaffaro LA , KruelCD, StellaSFet al. Transarterial embolization for hepatocellular carcinoma: a comparison between nonspherical PVA and microspheres. BioMed Res. Int2015, 435120 (2015).
   PubMed Web of Science ®Google Scholar
• Meyer T , KirkwoodA, RoughtonMet al. A randomised Phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br. J. Cancer108(6), 1252–1259 (2013).
   PubMed Web of Science ®Google Scholar
• Smits ML , Van Den BoschMA, NijsenJF, ZonnenbergBA. The evolution of radioembolisation. Lancet Oncol.13(12), e519 (2012).
   PubMed Web of Science ®Google Scholar
• Hilgard P , HamamiM, FoulyAEet al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology52(5), 1741–1749 (2010).
   PubMed Web of Science ®Google Scholar
• Salem R , LewandowskiRJ, MulcahyMFet al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology138(1), 52–64 (2010).
   PubMed Web of Science ®Google Scholar
• Sangro B , CarpaneseL, CianniRet al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology54(3), 868–878 (2011).
   PubMed Web of Science ®Google Scholar
• Salem R , LewandowskiRJ, KulikLet al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology140(2), 497–507 (2011).
   PubMed Web of Science ®Google Scholar
• Salem R , GilbertsenM, ButtZet al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin. Gastroenterol. Hepatol.11(10), 1358–1365, e1351 (2013).
   PubMed Web of Science ®Google Scholar
• Sangro B , Gil-AlzugarayB, RodriguezJet al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer112(7), 1538–1546 (2008).
   PubMed Web of Science ®Google Scholar
• Kennedy AS , McneillieP, DezarnWAet al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys74(5), 1494–1500 (2009).
   PubMed Web of Science ®Google Scholar
• Garin E , LenoirL, EdelineJet al. Boosted selective internal radiation therapy with 90y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur. J. Nucl. Med. Mol. Imaging40(7), 1057–1068 (2013).
   PubMed Web of Science ®Google Scholar
• Gaba RC , LewandowskiRJ, KulikLMet al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann. Surg. Oncol.16(6), 1587–1596 (2009).
   PubMed Web of Science ®Google Scholar
• Vouche M , HabibA, WardTJet al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology60(1), 192–201 (2014).
   PubMed Web of Science ®Google Scholar
• Garlipp B , De BaereT, DammRet al. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization. Hepatology59(5), 1864–1873 (2014).
   PubMed Web of Science ®Google Scholar
• Vouche M , LewandowskiRJ, AtassiRet al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J. Hepatol.59(5), 1029–1036 (2013).
   PubMed Web of Science ®Google Scholar
• Wang B , XuH, GaoZQ, NingHF, SunYQ, CaoGW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol.49(5), 523–529 (2008).
   PubMed Web of Science ®Google Scholar
• Ebert M , EbertJ, BergerG. Intravital microscopic research of microembolization with degradable starch microspheres. J. Drug Deliv.2013, 242060 (2013).
   PubMedGoogle Scholar
• Orlacchio A , ChegaiF, MerollaSet al. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J. Hepatol.7(12), 1694–1700 (2015).
   PubMedGoogle Scholar
• Bedouet L , VerretV, LouguetSet al. Anti-angiogenic drug delivery from hydrophilic resorbable embolization microspheres: an in vitro study with sunitinib and bevacizumab. Int. J. Pharm.484(1–2), 218–227 (2015).
   PubMedGoogle Scholar
• Fuchs K , BizePE, DenysA, BorchardG, JordanO. Sunitinib-eluting beads for chemoembolization: methods for in vitro evaluation of drug release. Int. J. Pharm.482(1–2), 68–74 (2015).
   PubMedGoogle Scholar
• Bize P , DuranR, FuchsKet al. Antitumoral effect of sunitinib-eluting beads in the rabbit VX2 tumor model. Radiology150361, doi:10.1148/radiol.2016150361 (2016) ( Epub ahead of print).
   Google Scholar
• Deschamps F , FarouilG, HollenbeckCet al. Comparison of pharmacokinetics and drug delivery properties of doxorubicin/Lipiodol® formulations in a hepatocellular carcinoma (HCC) rabbit VX2 model. P158. Presented atCIRSE 2015. Lisbon, Portugal, 26–30September 2015.
   Google Scholar
• Farouil G , DeschampsF, TselikasLet al. Evaluation of embolic effect, tumor selectivity, and anti-tumor efficacy of 3 doxorubicin/Lipiodol® formulations in a rabbit VX2 model. Abst 3006.3. Presented atCIRSE 2015. Lisbon, Portugal, 26–30September 2015.
   Google Scholar
• Sciarra A , RonotM, Di TommasoLet al. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver Int.35(11), 2466–2473 (2015).
   PubMed Web of Science ®Google Scholar
• Van De Maat GH , SeevinckPR, ElschotMet al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur. Radiol.23(3), 827–835 (2013).
   PubMed Web of Science ®Google Scholar